Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
- 1 January 2011
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 13 (1), 100-106
- https://doi.org/10.1093/eurjhf/hfq209
Abstract
Hospitalizations for acute heart failure syndromes (AHFS) are associated with high post-discharge mortality and readmission rates in spite of available therapies. Renin-angiotensin-aldosterone system (RAAS) antagonists improve outcomes in outpatients with heart failure (HF) and reduced ejection fraction, however these therapies have not been tested in AHFS. Aliskiren is a direct renin inhibitor (DRI) that is known to enhance RAAS inhibition, which may result in improved clinical outcomes in AHFS. The aim of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) study is to evaluate the effect of aliskiren on cardiovascular death and HF in AHFS patients. ASTRONAUT will be an event-driven trial with an estimated enrolment of 1782 patients hospitalized with worsening chronic HF, a left ventricular ejection fraction ≤40%, and an estimated glomerular filtration rate ≥40 mL/min/1.73 m(2). Patients will be randomized 1:1 in a double-blind fashion to receive aliskiren or placebo, in addition to standard HF therapy. The primary endpoint will be a composite of time to either cardiovascular death or first occurrence of HF re-hospitalization. Aliskiren is a DRI with a favourable neurohormonal and haemodynamic profile that may benefit patients hospitalized with worsening HF. Given the neurohormonal abnormalities that are present during and after hospitalization for AHFS, it is hypothesized that adding aliskiren to standard therapy will reduce post-discharge mortality and re-hospitalization. NCT00894387.Keywords
This publication has 35 references indexed in Scilit:
- The current and future management of acute heart failure syndromesEuropean Heart Journal, 2010
- Acute Heart Failure SyndromesJournal of the American College of Cardiology, 2009
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure: Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) ProgramJournal of the American College of Cardiology, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡European Journal of Heart Failure, 2008
- Heart Failure-Related Hospitalization in the U.S., 1979 to 2004Journal of the American College of Cardiology, 2008
- Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart FailureJournal of the American College of Cardiology, 2007
- Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart FailureJAMA, 2006
- EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of populationEuropean Heart Journal, 2006
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003